Motif Bio Share Chat (MTFB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Motif Bio Plc	LSE:MTFB	London	Ordinary Share	GB00BVVT4H71	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-0.048p	-6.98%	0.64p	0.63p	0.728p	0.728p	0.60p	0.60p	7,144,979	16:35:14

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-11.0	-3.9	-	2

Motif Bio Share Discussion Threads

Showing 4426 to 4446 of 4450 messages

Chat Pages: 178 177 176 175 174 173 172 171 170 169 168 167 Older

Date	Subject	Author	Discuss
18/10/2019 13:01	Deal about to be announced	w0lf0fwallstreet	Read Full Thread Reply
11/10/2019 08:28	Bit boring now from MMs, don't we see this every morning here a sell at ridiculous 15-20% discount!	zen12	Read Full Thread Reply
10/10/2019 14:39	No money - is that not why they raised 600k last week lol Now don't tell me that won't last long...it may give them enough time to do a deal, my guess they're already talking to many with Hercules.	zen12	Read Full Thread Reply
10/10/2019 14:06	Traditional Sale - Not as hope in HELL (imo) Shareholders will be very lucky if management are able to negotiate a "free assignment" of ALL research data and IP to another pharma in return for an agreement for a fee of ï¿½xxx,000 if new phase 3 results pass FDA and a y% royalty on ongoing sales - subject to which pharma the execution of the terms of this agreement might need to be insured by Lloyds or similar reputable insurance organisation against default.	pugugly	Read Full Thread Reply
10/10/2019 13:48	ZEN, sales talks take months. They have no money.	shirley83	Read Full Thread Reply
10/10/2019 13:41	All i know is that my shares are pretty much worthless now so I wont sell for a pittance. My fingers are crossed this comes good but if it doesn't its just beer money i'd lose now!	philoosh	Read Full Thread Reply
10/10/2019 13:30	HABP/VAP trial costlier & slower to recruit than cABSSSI (skin). ..... &, against what comparator? Still vancomycin? Or vs. linezolid, where there's some (albeit weak) evidence of superiority over vancomycin (unlike in ABSSSI). Directors keen to keep themselves occupied for a few more years at investors' expense.	vulgaris	Read Full Thread Reply
10/10/2019 13:08	the FDA led the board down a garden path for the last 3 years... and they continue to do so.. if there was a glimmer of hope of iclaprim passing they would have given a box warning.. sell to 0	pjj71	Read Full Thread Reply
10/10/2019 10:41	..if that was the case FDA wouldn't have been collaborating with MTBF since Feb (8 months), to agree the limited trial and its approval route. It looks like it's been simplified for whoever picks this up. We should now start to see interested parties come forward.	zen12	Read Full Thread Reply
10/10/2019 10:18	which pharma is going to spend more money after 2 failed phase 3 trials.. the FDA clearly dont want this compound to succeed hence the requirement for yet another trial costing millions and millions to quote the CEO...	pjj71	Read Full Thread Reply
10/10/2019 07:57	Nope, good news as FDA collaboration discussions over and now they know exactly what's needed. Let the sale talks now begin..	zen12	Read Full Thread Reply
10/10/2019 07:25	Looks like they are about to throw in the towel - That is reading between the lines of the announcement.	pugugly	Read Full Thread Reply
10/10/2019 07:22	oh dear... confirmation that the millions spent on the last trials were a complete waste.. who in their right mind would spend more on this wonder drug..	pjj71	Read Full Thread Reply
10/10/2019 07:10	No money, Need a partner, administration?	letmepass	Read Full Thread Reply
10/10/2019 07:03	Over and out	best1467	Read Full Thread Reply
09/10/2019 10:29	BoD need to issue the GM Circular RNS now. It's been a week since the announcement of it.	zen12	Read Full Thread Reply
08/10/2019 08:36	Haha LMFAO 100 shares traded... Wow.. Someone buying	letmepass	Read Full Thread Reply
07/10/2019 17:45	Lots of negative share chat here - growth today but lots of trading - interesting to see how the market reacts this month For those interested in pharma stocks Open Orphan ORPH is worth keeping an eye on - CEO Cathal Friel shown serious backing with £2 million of his own money in - predicts 40% growth a year on recent podcast hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year	sunningdale1	Read Full Thread Reply
07/10/2019 12:36	Ah shut up- what a pile of ï¿½&@( you most likely are!! How is that sort of posting helping anybody?	smcl	Read Full Thread Reply
07/10/2019 10:20	buywell3 - 20 Jun 2019 - 14:08:14 - 4002 of 4239 Motif Bio: Developing novel antibiotics to fight infection - MTFB Sometimes it pays to listen to a negative viewpoint This share was a case in question Links were posted to support the argument many times The post and subsequent ones were either ridiculed in the main by what I suppose were holders/rampers of the shares. This was my first heads up buywell3 - 18 Feb 2019 - 19:22:09 - 3279 of 4003 Motif Bio: Developing novel antibiotics to fight infection - MTFB I would imagine the FDA have a problem with the following 1. How does any person taking , or any doctor that may prescribe, this drug( if approved), know the exact state of the liver function in question, that will have to process the drug and thus because of the AUC problems identified by the FDA ,perhaps suffer damage ? 2. Assuming some sort of test could be made to assess the exact state of liver function of the patient to take the drug then there would most likely have to be at least 3 different dose options to choose from. 3. Risk of wrong dose options being prescribed then exist The FDA are going to play safe whatever , they have to withdraw enough approved drugs as it is. Around 50% of the FDA approved drugs that have to be withdrawn as a Class 1 recall(most serious) are due to guess what ? liver damage From original European submission back in 2009. A mild impaired hepatic function has a slight effect on the exposure of iclaprim (30% increase). AUC more than doubled in subjects with a moderate hepatic impairment. In case the dose was halved, AUC was only a little higher than the AUC observed in normal subjects. The SPC recommends no dose adjustment for subjects with a mild hepatic impairment, and a dose reduction of 50% for patients with a moderate hepatic impairment, which is agreed based upon the pharmacokinetic results.	buywell3	Read Full Thread Reply
05/10/2019 07:48	https://stocksrecorder.com/2019/10/05/uncategorized/motif-bio-plc-s-nasdaqmtfb-stock-price-up-9-7/	newtothisgame3	Read Full Thread Reply

Chat Pages: 178 177 176 175 174 173 172 171 170 169 168 167 Older

Your Recent History

LSE

MTFB

Motif Bio

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.